- Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin's lymphoma
- Results of study will be optimized by CGI to validate and enhance their proprietary genomic panel for DLBCL
A number of gains have recently been made in the treatment of B-cell malignancies, including the July 23 Food and Drug Administration approval of Gilead's Zydelig® for chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma. There are currently more than 600 clinical trials in phases II and III investigating drugs for DLBCL and some 1,500 for B-cell malignancies. In addition to offering improved diagnosis and prognostic information for patients with non-Hodgkin's lymphomas and leukemias, CGI's proprietary tests allow biotech and biopharma customers to more efficiently stratify and monitor patients enrolled in these clinical trials.Cancer Genetics, Inc. and Siddiqi recently completed another collaborative study on CD23+ diffuse nodal follicular lymphoma. Preliminary results of this study will be reported in an oral presentation in the 17 th Meeting of the European Association for Hematopathology, to be held in Istanbul, October 17-22, 2014. Siddiqi has no financial ties to Cancer Genetics Inc. About Cancer Genetics Cancer Genetics Inc. (Nasdaq:CGIX) is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see http://www.cancergenetics.com. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Media Relations Paul Kuntz RedChip Companies, Inc. 800-733-2447, ext. 105 firstname.lastname@example.org Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6997